Related references
Note: Only part of the references are listed.Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
Anna-Maria Hoffmann-Vold et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
Dinesh Khanna et al.
LANCET RESPIRATORY MEDICINE (2020)
Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient-Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II
Elizabeth R. Volkmann et al.
ACR OPEN RHEUMATOLOGY (2020)
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
Oliver Distler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Interstitial lung disease in systemic sclerosis: current and future treatment
Roberto Giacomelli et al.
RHEUMATOLOGY INTERNATIONAL (2017)
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial
Donald P. Tashkin et al.
LANCET RESPIRATORY MEDICINE (2016)
Mortality and survival in systemic sclerosis: Systematic review and meta-analysis
Manuel Rubio-Rivas et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2014)
Changes in causes of death in systemic sclerosis, 1972-2002
Virginia D. Steen et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Cyclophosphamide versus placebo in scleroderma lung disease
Donald P. Tashkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Share Paper
